Rigel Pharmaceuticals (RIGL) 7 Nov 232023 Q3 Earnings call transcript

Greetings and welcome to Rigel Pharmaceuticals financial conference call for the third quarter of 2023. [Operator Instructions] A brief question-and-answer session will follow the formal presentation. [Operator Instructions]As a reminder, this conference is being recorded.It's now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel and Corporate Secretary. Thank you. Mr. Furey, you may begin.

quarter results third call. update our to XXXX business financial conference Welcome product along for this outlook financial third Events a ago during regarding short viewed the release section statements and make forward-looking today's our the XXXX be A plans development. site for and reminder, a of quarter our Investor press on News in timing, regulatory presentation the was and Relations issued and can call, financial with & may slides rigel.com.As our while we These are and that statements to subject uncertainties differ may risks to results from cause actual those forecasted. quarter risks be subsequent report Report and year on XX-Q these of description SEC. on recent for December most ended in filings Annual with A Form Form the quarterly XX-K the can third file with found the XXXX, our SEC, XX, on our including Any events only forward-looking date, to call Chief Raul President and undertake no of forward-looking Rodriguez. circumstances.At Executive to like Officer, to and our turn or reflect would this we today's statements statements update I to these made obligation subsequent over as are the time, Raul?

you, on for  Thank Schorno, and thank Chief Dean Officer; our me me Chief Dave everyone you, Commercial and with joining today. Officer.Let our Financial Slide today Ray, X. are begin Also Santos,

progress with an coupled third presentation. our tight on growing we plans made financial during the components today's Rigel, allowed The meaningful on was of important growth, breakeven. one We'll review the discipline quarter to progress products. to commercial sales for one in important make This this which reach of financial us our

to grew XX% product approved chronic launch. first we quarterly In reached robust sales. for a XX% ITP. patients product, quarter-over-quarter net our We a clinics for product year-over-year. since third new TAVALISSE, by quarter, adult record and sales and delivered Regarding the Demand bottles shipped performance

momentum team continued our generating are that the is for TAVALISSE. with pleased We

week, as we second in mutant IDHX of bottles shipped increased in AML, the ASH community quarter our and the refractory new highlight through saw we to We last to our clinics patients AML announced data for refractory new the adult development supportive engaging the or awareness further institutional the positive several programs. medical product product, REZLIDHIA relapsed ASH our continued mutant IDHX at third populations. approved REZLIDHIA, poster team.Just presentations include For we growth awareness raise look meeting our products.Shifting in meeting, forward relapsed with various at which to or patient on to sales and

IRAKX/X we extremely from groups expect we lower-risk initial focused enrolling our and cost-efficient in dose inhibitor in cohort, for With third we're Here, all results Phase are our mid-XXXX. MDS, and Xb efforts. RXXX, currently in the

further continue and cancers in additional in-license with synergistic to broaden We as this believe from modest. pipeline us that our our commercial important This discipline.Now more quarter in-house on to In plan We past Dave? in late-stage good opportunities leverage our funded Dave from our particularly where in was expense plays on in our be assess growth to expand based with own AML IDHX investments role. mutant and review and starting will will the in evaluate plan internal olutasidenib We variety financial made modest, focused a we commercial our a to addition, clinical options has to products on business a detail to financial that development is plan potential for opportunities be pipeline, on reach strong this more let hematology/oncology business. settings later presentation.In of breakeven. this I business. olutasidenib. our continue in We Hem/Onc progress capabilities. our are summary, touch we

Thank you, Raul.

achieved which another in TAVALISSE, patients of new during and back-to-back to QX, our the over continued is X, progress quarterly thrombocytopenia high achieved report Slide for bottles is minutes to starting another XX% X. in to TAVALISSE in months REZLIDHIA first for to QX Slide a of quarter growth few take XXXX. record our with the new Now you'll quarter previous launch fourth high and X,XXX to TAVALISSE. with We cITP, all-time shipping X we I'd like clinics, impressive sequential patients response an to patients shipped continuing discuss number of more that consecutive yet TAVALISSE had our I'm for growth to to and in our record FDA-approved resulting with of patients clinics with insufficient a since chronic or the treatment.Moving a bottles an immune and adult launch, grow demand the excited who've see indication XXXX.On

For quarter consistently TAVALISSE records of achievement demonstrates continued focus our high is QX, we more patients quarter $X.X produced in our TAVALISSE We achieve last and to improving than XX% more same excited sales.Our the sequential bringing very growth. above to million TAVALISSE year-over-year record representing million, net sales that were driving strong of on growth. net this $XX.X new year, quarterly refill business

with during have pleased our TAVALISSE XXXX how are year. close as and we this out business maintaining to forward the We look we expanded momentum

have focused identify stay last new our to how trending appropriate on who We little patients on our growing can over clinicians years. patient Slide starts.And the more to continue detail will TAVALISSE new X patient X provides been targeting benefit from starts a

reopening have new clinicians of then, of more durable been levels awareness our the platelet with second moved starts reaching year. we starts our As and the we since force were patient Then starts. that challenged on as efficacy in our growing time, to XXXX, in sales patient during into began improving with pandemic, quarter XXXX focus growing TAVALISSE's new improve you'll recall, and in post-COVID expansion consistently. spreading the new patient Ever over we

acute relapsed FDA-approved beyond. well through review XXXX.On you progress leukemia IDHX first continues see of XXXX, trends there CAGR for the few our strong Slide and unmet with XX, to produced.Moving into the myeloid REZLIDHIA targeted which quarter longer the a and AML, double-digit that for as months on indication XX, test.To treatments our refractory to of patients our fact, In is I'll have by relapsed for will launching and of of in for year-to-date continued Slide FDA-approved are susceptible and needed. I'm detected adult a discuss TAVALISSE response an and take REZLIDHIA, an of XXXX final or team mutation Overall, toxicity durations efficacy XX%, X. very growth since bodes refractory X particular, efficacious be move agents that we acceptable to of minutes need continued and growth in provide or an proud brand Slide we with balance as quarter achieved the

relapse bringing each of intensive representing year.Slide needs XX% mutation, sold strongly mutant in patients. third that We shipped our X,XXX in $X.X launch.Moving or refractory been And clinics We and the treated quarter most December view of we our impact in total REZLIDHIA. in over quarter, or in patients of lives diagnosed bottles $X.X research We XX continue REZLIDHIA addresses and to total those in sales or American of are opportunity focus near-term of sold late patients the to product will XXX of REZLIDHIA to ongoing million. XX,XXX whether XXX the Slide patients of patients, Overall, shows the million have refractory this during XX patient the to launch-to-date inventory has than with believe therapy We available net resulting patients net to patients progress with Cancer fewer a growth eligible X IDHX that that than we more our estimates X,XXX distributors became a and new With of be XX our relapsed those setting not, since for reduced sales. the ship X% those QX. X% are AML. we clinics showed bottles The Society population achieved REZLIDHIA believe hand. to and bottles XXXX, years. we have currently to continued our within that IDHX as having the patients on launch-to-date around

REZLIDHIA, teams We on XX. particularly new of REZLIDHIA through to focused building on field month activities.Moving to in Slide accounts. vary that awareness our patient other starts or mutant key With to within IDHX launch improving patient continue progress launch can we are refractory report starts in a rare starts want a on and is I to share Because relapsed disease, and AML REZLIDHIA new institutional period, month remain context, our surged single that September. pleased new month. QX, still I'm within awareness to during this from level of to patient highest growing our

occurred adoption key patients grow some patient of We was a Importantly, of starts. as more that as institutions across were X new starting It in see improvement their and believe first both accounts. this key our reasons. academic combination monthly to this by pleased depth very on institutions high driven REZLIDHIA.We institutional starting institutional breadth institutional was well because

leukemia a potential team population exciting and in the business plan.My refractory have Data our members AML efforts significantly was mutant to are we IDHX First, thanks we forward to this of evidence have during a new for as our an that REZLIDHIA Slide accounts. institutional AML that a has accounts become significant the Efficacy the major institutions. success September looking conference and see critically including to AML. is in previous and XXXX to that our venetoclax by was with who XXXX additional new And will ASH mutant clinicians the presented a ASH. population at AML year be our responses their launch to with failed many and influence REZLIDHIA, and hematology this a to during key of on a we the to as team specialists. We compelling team presence have institutional first to segments see of patient for refractory and institutional both impact, important All September new the improved awareness our the new our REZLIDHIA were awareness promising all updates to in I in as treaters continues affairs result, for to new in venetoclax. and the audience of shown that successfully grow population the REZLIDHIA medical raise therapies, short be in a population. in HCP It market-leading REZLIDHIA Rigel's first and important to graph QX. our to this difficult starts business both year nearly these bodes continue and REZLIDHIA. increase or mutant Slide driven or continues strengthen. Overall, in REZLIDHIA's needs to XX% move the we In improve the are has refractory displaying launch.Moving right, as data a we in targeting team future.Finally, to our move believe patient right launch forward we patients in approved And we community we of brief as discussed, And forward ability of EHA key that the have we providing particularly that launch by X business awareness had products and as in very feedback time, receive are months institutional patient we address the at Based our will XX. key to word treat. patient this have broader accounts to you our we you important their QX look deployed onboarded In on community.Overall, is efficacy in improved. on second IDHX is institutional that continuing through in treaters.Secondly encouraged believe key track in olutasidenib consideration IDHX TAVALISSE supports patient will importantly, especially move saw relapsed treatment well starts, is improving this of the potential as on XX, believe we into REZLIDHIA impressive on relapsed treatment just post leukemia both treaters. key very execute durable at patient is and

standpoint. in We a from strong promotional and a have Diego, presence both will scientific San

Raul evidence olutasidenib have IDHX mutant patients key outside will presented from we venetoclax highlighting population. pivotal populations attention, Phase more forward from side, we'll be course, to your additional will and awareness scientific at ASH, And update Raul? call back patient showcasing raising and data our the brief to our Thanks the with growing the TAVALISSE Hem/Onc cohorts.We're pipeline On I/II for Rigel, now to portfolio, more of development the trial providing looking REZLIDHIA. our I turn post along a of progress. relapsed/refractory on and Rigel's provide over

our on expand of expansion There our summarize now are further. provide development XX. other We of and will to our olutasidenib business, X the I we plans commercial want Dave. our business you, for and like programs.Beginning Thank updates accomplishing this. even Slide on growth ways

products with potential the to new there First, with new data -- is our indications. current supportive potential grow and particularly

other and the additional Hem/Onc data development be cost-efficient investments and operations. be In and numerous best than MDSs new will in-licensing own resources.Any in trials AML, products. We we think funded new for indications there plays opportunities also potential an potential segments has cancers olutasidenib mutant and role. this by the indications, our promising and can provide will Based in-depth through sponsored see through in we potential our addition, investigator IDHX use is Fostamatinib own rather additional has we of glioma trials. As a believe review, our of focused for olutasidenib. is on in that where

approved we partners this this, in-licensing of to right a with side infrastructure. is efforts.Moving our slide. the strategic Hem/Onc part existing was synergistic these Rigel on also with work and to new of that in-licensing academic an The success with with of on our and centers provided of synergistic to are government expect assets the REZLIDHIA As We continue replicate that as look capabilities. evaluate we highly this product to

late-stage We commercial early and to the are approval where review potential are of approved looking products.Moving have in stages XX. related for Hem/Onc and or their we areas in are assets on that Slide launch development adjacent clinical and or the to already complementary for that

present in cell suggests benefits a our alone and I evaluate helps in abstracts or or the analysis reporting The were hoc IDHX sales December. analysis subset olutasidenib of MDS. with wanted ivosidenib at refractory results our or I/II complete patients relapsed that subset will or results azacitidine MDS. in trial highlight combination As MDS, remissions stem patients. abstract these reports transplant, providing a with This treatments.Abstract a we from of XX alone with clinically combination to answers clinicians, IDHX pipeline. and us activity with in induce or to hematopoietic encouraging encouraging in in treating frequent with of in Dave Phase show post data this mentioned, upcoming azacitidine and XXXX, receive prior with expansion a few These patients data IDHX the presented or be a in ASH generating meaningful additional question olutasidenib of we that olutasidenib has the may there mutant patients in refractory mutant AML meeting relapsed patients delighted mutant that these XXXX from are product venetoclax. to Included

to that Our providing is of RXXX in lower-risk in treatment which partner will well. in patients highlighting IRAKX/X XXXX of fostamatinib in in of trial.Moving a in Japanese MDS. primary second-line of think a Phase Kissei Xb These the primary on long-term their with as unmet results spend on XXXX, could the moment study, fostamatinib lastly, wanted overview to ITP. enrolling III how including abstract progress a we spend safety and support treatment use ITP.And a with study trial few the abstract our post patients present efficacy now discussing will XX. for Slide inhibitor moments address RXXX lower-risk the need I landscape Phase MDS, is I an

in may a is the marrow. hematopoiesis know, in you hematopoietic disorder stem resulting the bone MDS ineffective and cells, dysplasia As of

and risk undergo limited for a therapy AML with common. progression this of Subsets autoimmune setting prognosis poor significant first-line different include Durable of events.Loss MDS, and patients represents to lower-risk with in result associated second-line hematologic responses, on patients the cytopenias. not even second-line as agents responses significant and following death. and shown response show the are Patients For these setting in abnormalities, morbidity second-line in adverse patients slide. cytopenias, treatments

mid-XXXX.Moving to need, are who our of study RXXX MDS have this lower-risk RXXX to study this are shows to there third remains Enrollment address unmet is For and progress well. Phase potential a to MDS. currently patients patients resistant XX and XX. open-label lower-risk need data we therapies, underway, Slide current patient to with cohort underserved who refractory we in has the ongoing on population.Slide Xb believe or the significant preliminary in in expect continues The in

Lilly. call is in Xa our Eli turn to Our are partner, Dean. with advancing arthritis.With will RIPKX in study rheumatoid Phase over inhibitor, that, I this their They RXXX, program the

I'm you, Thank Raul. on Slide XX.

and bottles quarter. the at the For we while shipped to remaining patients distribution in of of shipped our with to third quarter channels TAVALISSE our million resulting XXXX, sales. product bottles X,XXX were specialty end X,XXX the increased of distributors, bottles $XX.X the gross XXX of clinics, in TAVALISSE levels

TAVALISSE models of the quarter of and distribution distributors, shipped specialty net million product the third sales of REZLIDHIA were XXXX, quarter quarter XX a bottles of third the while third REZLIDHIA reported increase million We $X.X remaining of net end XXXX.We XXX product the same the quarter. at patients of in gross from REZLIDHIA the in from our sales. channels of in reported period product shipped XXXX. our the XX% we XXX sales bottles levels in of to resulting $X.X compared XXXX, clinics, $XX.X of For decreased in to to million

sales net allowances discounts, co-pay from TAVALISSE and REZLIDHIA were returns, estimate rebates, net other recorded of $XX.X assistance and product of chargebacks, million. Our

For and TAVALISSE gross for to and REZLIDHIA was XX.X% net our third respectively. adjustment XX% quarter of approximately the gross product of XXXX, sales,

from on let of quarter product review our expectations net for Before we move XXXX. fourth sales, me the

the our to with year.Incrementally, clinics a to I bottle inventory variable slide. the our of approximately continue be our we in remaining strength for shift XX% to remainder We third approximately next and end increase our TAVALISSE. expect Incrementally, for On gross in XXX in XX% the to strength the levels and continued the of quarter highlight expect business are bottle would quarter be saw of and in our see the levels the pleased of to These outside REZLIDHIA. net patients the we and in adjustment XXXX that control. of quarter fourth at channels distribution TAVALISSE the to for for

addition XXXX, and approximately $X million In sales revenues Rigel's ended to primarily Grifols.Moving were months XX, X the on product contract September from collaborations expenses. for costs from net to

primarily and of related third of expense offset XXXX research $XX.X quarter Our the $XX.X Total the by to we've this in million XXXX. third development This development you'll anemia of our leverage period of $XX and to was decreased within timing operating related REZLIDHIA quarter is cost costs recorded of $X.X seen the increased the lower where upfront our activities this focused a expense due for costs to a clinical were able discipline approximately These research the across to range. million successfully in XXXX. cost settings in is cost inhibitor costs and the We're compared same have XXXX. The note, entire autoimmune therapeutics decrease the and in partially seeing IRAKX/X COVID-XX, to spending with level in structure. million facility-related and million efforts community our was and launch of pleased quarter development sales that been trials with product the organization. both along were warm academic with hemolytic second financial program.As we're result the III due and our fostamatinib of to in expenses decreases of Phase third payment quarter form operating

in look equivalents to ended we increase over to certain see $XX.X to cash quarter maintain in cash, due operating the quarter I'd fourth million.With back investments to approach call an turn of events, focused into the we and short-term like We with this disciplined future. that, programs Raul. Raul? the and and expect the expense do While to

Thank you, Dean.

with growth. have another of made strong proud delivering far marked so continued we are in sales XXXX, We by the TAVALISSE quarter progress

REZLIDHIA driving community We medical are sales awareness including upcoming teams launch at executing of December. our conferences, engagements on the meeting through our in and and the with ASH

with this call and to breakeven. of you company.With quarter, set financial own our it since progress have in which in are towards I us will a and from own our good have will creating progress important financial important we growth in now Continued an apart This made coupled for and operations own our open a our run objective, allow quarter, grow to with we diligent Rigel the of company operation, our resulted believe and discipline our will your products, our thank questions. your reaching cash. We that, self-sustaining interest is goal particularly

[Operator from Jefferies. comes of with Instructions] line the The Yang first question Eun

This on is Nalin for Eun.

$X exclusivity And for product expiration So the run product Japan? expect could please Europe you rate with in inflection point? you or sales for TAVALISSE in million, there And you sales the remind TAVALISSE, to us question do sales increases the would U.S., about be? the for on market first big gradual be do -- to an REZLIDHIA, then on and quarterly of expect the how

on I'll to and answer U.S. first ask Ray the elsewhere. exclusivity TAVALISSE in question

Yes.

We expected back have for until September composition elsewhere. TAVALISSE patent is of matter PTA run Japan to have and to to you it's and that check on exclusivity in with a PTE, I'd XXXX. get of and

I it's similar. or comparable think

don't is Yes. It comparable. exact the dates. have I

comment to want you do Dave, REZLIDHIA, on our On view?

a in From here launch. still of REZLIDHIA, we standpoint early Yes. the are

You have inhibitor have clinicians years for remember IDHX that now. one using X been to

has be piece here And quite you so the some we carryover. move into refills think has REZLIDHIA. with I because time. expect year. the I That's which carryover part we make thing leukemia that's one But other bring of a other part business that Those been patients, and we'll will up get, of TAVALISSE it as is new new that long I the a patients to we sure the for patients, going duration get, the is good something to have is that want take same next that response,

they is every going people than time responding, composite are complete well obviously, that have they patients judge remission then And they'll remember and They're you'll because the XX%. on new on keep continue. of But start are whether late X will response product responses. REZLIDHIA, then to our months there by not. And it's So these we a product.We if upwards on more patients do starts for patient business try stay grow -- and help the to before a themselves. or at had the least

why that's the in So only We're in we're early still full launch. of quarter third this. very

And some so hope the already. grow. why color sales to I started helps the of around really that carryover we patients we that REZLIDHIA benefit that haven't seen with we've put expect

one Currently, ask to what in on may of follow-up second-line TAVALISSE. users need I percent the market? what you capture ITP? line further in If the order And are would second

But we didn't So from that. about really in time and that our patients database. the our for have data second line. in been getting quarter, have second used line. where readily by second a are therapy we so in and we're that quite you our I of that's on RIGEL Rituxan at third TAVALISSE long any is this showed are and provide happy of of as a very third that ONECARE really And market line about are comes quarter, XX% stayed XX% consistent -- or showed XX% why either that of TPOs line, And update last pretty in least database patients

we'll to, been try really, of continue and So doing. that's key I to is grow But the to patient up. what we've patients think move course, new starts, continuing

that answers hopefully, question. So your

from Fitzgerald. comes Kluska question the next line with Kristen of The Cantor

Rick on for Miller This is Kristen.

of approach focus there, educational the institutional the how commentary past sales of or thinking at from strategy approach force in may year do Given approaching institutional REZLIDHIA TAVALISSE aspects the force sort your and the the approach? on conference you the sort differ any about how with sales commercial ASH have given new the of you're dovetailing this

do Dave, Rick. question, Good want to comment? you

is, are hematology treaters interact think important their to customers. opportunity Yes, important ASH. them attend bringing I institutional will we our to it's ASH an entire we with team do most fact for The say is because

And so especially it's audience, AML treaters. a very specific

will And be we there. so deploying team our

middle information the it's on we a have days able ago, created ASH the centers. before And team the year year, be the academic the -- to just And we remarkable, this institutional Rick, there on approved to we REZLIDHIA. Meeting. booth us ready then, in were product since the create we of got penetrate help business and

much in So year of different we're preparedness very year a ago. this than very, terms

with Very, it of different. of for these exciting interact both clinicians should those an meeting but very be academic also of lots And many able for to so community-based products. being us, center,

use also other data the compelling.And data have of earlier REZLIDHIA. I is being places, We published this EHA year in at that presented think we very and supporting

guess, So at a different, and ago. this I to information we share really this data Meeting individuals approach, to very ASH year have relative a

just maybe bit thinking MDS positive ASH IDHX how analysis. specifically talk to a AML. And you're with population the follow-up this MDS abstracts, in you're in one about prevalence the and how the Can the about little you relates what seeing

Looking forward in team San to the Diego. seeing

seen comment. I'll as inhibitors Dave, an Yes, We've opportunity. IDHX do MDS this comment work to is you want well? attractive in area.

So it provides some exciting opportunities.

it colleagues you, with remind to our in Just by included in patients the Phase done MDS. study II Forma,

XX idea some think, already with, I that on have patients. So opportunity we

just, right. Yes. abstract question? sure that first part got you the ASH. your the Rick, just In I at I presented just repeat And to want could make of

of more market Yes, size around AML. versus prevalence MDS sort population just in and the

is here have those but the me, than I a it population. smaller AML with right Yes, population don't specifics

just higher think bit than but it's positive AML. I in I percentage the smaller Yes, think is of a IDH

So population -- but it's on smaller still whole. a the

Next questions are from the Citi. of Yigal line with Nochomovitz

on REZLIDHIA. Carly is few follow-ups for had We This a Yigal. on

And versus patients of believe share third have approximately within if contribution you incident patient existing details you that maybe if future get curious opportunities you then from percent market population? you quarter the wondering the outlined, can during different the the on the one First, new what and comment the might of there's we your on plans highlight expansion that there? label you would as highest just second, priority more when and

patients comment share on Dave, do incident REZLIDHIA population? of you want and contribution, established versus to new

Yes.

in see previous. to to you're those majority carryover probably in September. have So I'd them, total lot to X/X our looking got always -- patients, at get here, We X/X those were bottles QX, it's on and me that maybe And about again, carryover patients. the if when from X/X of let obviously, said, shipped as new new our is a depends I generally you of X/X new.

the So number the that's way is think that like I -- is why is. or it way

but was lot in that is carryover. patients So if majority because is patients sense, again, those, you quarter. a of that showed I hope up a kind talking you're And second lumpy, terms about of XXX share in do your this maybe of really question it makes of the quarter -- our this, September.On because new

You were our quarter, launch, we from patients. XX heard first our around

of we're incident think we new share double-digit that probably So in patients.

and the X other. are to a mentioned, product the and setting. segments are and on attractive things MDS we that And first thinking of in line and the other in has that I about. patient's shown in one label those AML, benefit within in priority, others, expansion fact, Obviously, there different of AML all the opportunities are maintenance relapsed/refractory we're know that in other works glioma

sizable, and in ago, exciting mentioned In area perhaps. treated need a a so an and poorly, low-risk a a poorly just as larger well, we with is opportunity opportunity, as is minute sizable significant both high-risk smaller, today. just very That medical addition, glioma MDS, opportunity while And MDS.

cases, in of we clearly, on varied different perhaps those highly And a academic going manner, focused, are and is opportunities so really a some a efficient for and partners. of there array cost-wise do with olutasidenib. to subset focus So government with

from is question Wainwright. Pantginis of Joe with H.C. next The the line

I'll but you of you I go TAVALISSE data the I curious, granularity in to don't first, know the was to I question, collect. And I populations. patient level have back ask So wanted this guess if

you're replacing lieu do line that you data that second moving have or of Rituxan? Do TPOs? say, TPOs you granularity that the -- level TAVALISSE are in that say, second-line have or example, show, So for patients, that prescribing in patients of you're to or,

comes actually -- clear, We we just I -- Well, is is. we our Rock. know those where data histories, to line from be what because therapy have of that

So -- of they intended don't what we we use. don't kind have would have what is to

sense? things chosen XX% are they used in So don't second of have what that know there. kind of we we're those would are Does mixing The of line, data had they we X terms TAVALISSE. going make but through that are not sharing patients different that Rock

does. It

our do experience TAVALISSE ATU, up think and just move I how because tend are clinicians TAVALISSE -- very works with line, those to it they it's predictable. who've from use had they it So clinicians those like who second

way where is second best about from any have it. can of product they would line in to to the don't say probably terms business that's I So conclusions what I our jump coming want chosen.

there becoming with REZLIDHIA, to syndrome one at regard to the to potential continues the more there is signals, I to fact physicians handling real-world that with label. much Is and discuss then regard for impressive. upon any And guess the wanted And safety of obviously, to on differentiation since I be launch that? anything warnings example, are it the touch adept

is class No, indicates we this inhibitors as class, It's and IDHX . effect. say across a well that as I FLTX with both -- the IDHX look, have a box wouldn't anything black warning inhibitors

that believe So certain we said, that it's reason effect have a believe a do it or REZLIDHIA. differentiation for do believe would label that That to and to for have our different might And that we reference is differentiator comorbidities. anything class differentiator who we is cardiac have needing syndrome be a heard any not to in patients of the our cardiac toxicity do lack a monitoring profile.

will something and continues look future that in help be into to we with to the potentially, evidence that real-world show that. So hopefully,

like the Rodriguez Raul Mr. comments. questions are time. floor turn to And at back There no to further for over this closing I would

Thank you.

our very This We quarter on as one. well. a that. nicely, good progress was our financial good -- happy very with We we're and really grew goals products made

we're pleased very are. So where we

for that, work lives calls. patients. great And of as Rigel. to with always, their for the hard of support commitment every like by your to close one So interest single to to Have improving look employees with and I'd like you And on thank I day. continued They day. a our of future you every I'd updating thanking forward that,

teleconference. concludes today's This

time. You Thank your for lines participation. may disconnect your you at this